Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579940PMC
http://dx.doi.org/10.1161/JAHA.115.001896DOI Listing

Publication Analysis

Top Keywords

glucocorticoid therapy
4
therapy duchenne
4
duchenne cardiomyopathy
4
cardiomyopathy hobson's
4
hobson's choice?
4
glucocorticoid
1
duchenne
1
cardiomyopathy
1
hobson's
1
choice?
1

Similar Publications

Mild liver injury following withdrawal of long-term prednisone therapy: A case report.

World J Gastroenterol

January 2025

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, China.

Background: Liver injury manifesting as hepatic enzyme abnormalities, has been occasionally identified to be a feature of primary or secondary Addison's disease, an uncommon endocrine disease characterized by adrenal insufficiency. There have been no more than 30 reported cases of liver injury explicitly attributed to Addison's disease. Liver injury resulting from adrenal insufficiency due to glucocorticoid withdrawal is exceptionally rarer.

View Article and Find Full Text PDF

Background: Primary coenzyme Q10 (CoQ10) deficiency is an autosomal recessive genetic disease caused by mitochondrial dysfunction. Variants in Coenzyme Q8B () can cause primary CoQ10 deficiency. -related glomerulopathy is a recently recognized glomerular disease that most often presents as steroid-resistant nephrotic syndrome (SRNS) in childhood.

View Article and Find Full Text PDF

Rare mixed dementia: A case report.

World J Radiol

January 2025

Laboratory of Functional Chemistry and Nutrition of Food, Northwest A&F University, Yangling 712100, Shanxi Province, China.

Background: Autoimmune encephalitis (AE) is a rare and recently described neuroinflammatory disease associated with specific autoantibodies. Anti-leucine-rich glioma inactivated 1 (anti-LGI1) encephalitis is a rare but treatable type of AE discovered in recent years. Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia.

View Article and Find Full Text PDF

Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer, tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial demonstrated that the most common treatment-emergent adverse events were cytokine release syndrome (53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), and an emia (30%).

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates predictors of cytomegalovirus (CMV) infection in immunosuppressed patients with connective tissue disease undergoing pulsed-methylprednisolone (p-MPSL) therapy.
  • It is a retrospective cohort study that analyzed 200 patients' data, identifying key baseline characteristics linked to increased risk of CMV infection, including age, platelet count, lymphocyte count, and specific blood ratio metrics.
  • The findings highlight that older age and low blood cell counts significantly elevate the likelihood of CMV antigen positivity, providing insights for risk assessment in similar patient populations.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!